Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $3,457,585.41 in Stock

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 23,619 shares of the company’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $146.39, for a total transaction of $3,457,585.41. Following the completion of the sale, the chief financial officer directly owned 225,364 shares in the company, valued at approximately $32,991,035.96. The trade was a 9.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Aaron Freidin also recently made the following trade(s):

• On Monday, September 21st, Aaron Freidin sold 4,100 shares of GRAIL stock. The stock was sold at an average price of $93.34, for a total transaction of $382,694.00.
• On Thursday, August 27th, Aaron Freidin sold 7,900 shares of GRAIL stock. The shares were sold at an average price of $85.01, for a total transaction of $671,579.00.

GRAIL Trading Up 6.0%

GRAL stock opened at $140.58 on Friday. GRAIL, Inc. has a 1-year low of $41.50 and a 1-year high of $166.48. The business’s 50-day moving average price is $92.37 and its two-hundred day moving average price is $72.07. The firm has a market cap of $6.28 billion, a PE ratio of -14.42 and a beta of 2.83.

GRAIL (NASDAQ:GRAL) last announced its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. The business had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. On average, analysts forecast that GRAIL, Inc. will post -10.41 earnings per share for the current year.

Analyst Ratings Changes

GRAL has been the subject of several research analyst reports. Guggenheim boosted their target price on GRAIL from $75.00 to $155.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Canaccord Genuity Group increased their target price on shares of GRAIL from $80.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. Robert W. Baird boosted their target price on GRAIL from $96.00 to $118.00 and gave the company an “outperform” rating in a research report on Tuesday, September 22nd. TD Cowen reiterated a “buy” rating on shares of GRAIL in a report on Thursday, September 24th. Finally, Mizuho upped their target price on GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a research report on Friday, September 25th. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, GRAIL currently has a consensus rating of “Hold” and an average price target of $102.70.

Institutional Investors Weigh In On GRAIL

A number of institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC lifted its position in GRAIL by 30.3% in the 3rd quarter. GAMMA Investing LLC now owns 1,273 shares of the company’s stock worth $178,000 after buying an additional 296 shares during the last quarter. CoreCap Advisors LLC lifted its stake in GRAIL by 107,400.0% in the third quarter. CoreCap Advisors LLC now owns 1,075 shares of the company’s stock worth $151,000 after purchasing an additional 1,074 shares during the last quarter. Moody National Bank Trust Division boosted its position in GRAIL by 1.3% during the third quarter. Moody National Bank Trust Division now owns 13,478 shares of the company’s stock valued at $1,889,000 after buying an additional 178 shares during the period. State Street Corp increased its holdings in shares of GRAIL by 26.1% in the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock worth $162,859,000 after buying an additional 493,621 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of GRAIL by 26.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,597 shares of the company’s stock valued at $1,474,000 after acquiring an additional 4,498 shares during the last quarter.

GRAIL Company Profile

GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.